--- title: "RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights" description: "Rosen Law Firm is urging Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stockholders who have incurred losses exceeding $100K to contact them regarding their rights. A class action lawsuit has been filed" type: "news" locale: "en" url: "https://longbridge.com/en/news/251303959.md" published_at: "2025-08-02T21:25:32.000Z" --- # RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights > Rosen Law Firm is urging Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) stockholders who have incurred losses exceeding $100K to contact them regarding their rights. A class action lawsuit has been filed for investors who purchased securities between September 17, 2024, and May 26, 2025, alleging that the company misled investors about the effectiveness and safety of its RP-A501 treatment. Shareholders interested in leading the class must file motions by August 11, 2025. Rosen Law Firm operates on a contingency fee basis, ensuring no upfront costs for shareholders. **RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals,** **Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights** Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501’s clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event (“SAE”); (4) accordingly, RP-A501’s safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250802688652/en/ ### Related Stocks - [RCKT.US - Rocket Pharma](https://longbridge.com/en/quote/RCKT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 10:08 ETRokt Joins American Heart Association's "Go Red. Shop with Heart" Initiative, Marks Kickoff at NYSE Bell Ringing | Rokt, a leading ecommerce technology company, has joined the American Heart Association's "Go Red. Shop with Heart" init | [Link](https://longbridge.com/en/news/275145288.md) | | Rocket Doctor AI Grants Stock Options and Restricted Share Units to Consultants | Rocket Doctor AI Inc. has granted 33,353 stock options at $0.77 per share and 205,065 restricted share units to consulta | [Link](https://longbridge.com/en/news/274366738.md) | | Rocket Doctor Engages Danayi Capital for Digital Marketing Services \| AIRDF Stock News | Rocket Doctor AI Inc. has engaged Danayi Capital Corp. for digital marketing services for two months starting February 9 | [Link](https://longbridge.com/en/news/274367082.md) | | Rocket Doctor AI Secures In-Network Contract With Major U.S. Insurer Covering 175,000 California Members | Rocket Doctor AI Inc. has secured a contract with a major U.S. insurer, expanding its digital health platform to 175,000 | [Link](https://longbridge.com/en/news/273874717.md) | | Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT) | Wedbush analyst Yun Zhong has reaffirmed a Buy rating on Rocket Pharmaceuticals (RCKT) with a price target of $16.00. Zh | [Link](https://longbridge.com/en/news/264863677.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.